Fig. 3
Bloodwork and PBMC proliferative response in FCGS patients receiving ASC treatment. Changes in a percentage of CD8+ T cells and b CD4+/CD8+ T cell ratio; c percentage of CD8+ T cell with CD8 receptor downregulation (CD8lo cells) out of total CD8+ T cells; and d serum globulin level, measured prior to and after ASC administration. Note the significant reduction in serum globulins in responder cats corresponded to clinical improvement. Reduction in CD8lo cells was also significant between pre- and post-ASC therapy. Representative flow cytometry plots for CD8+ and CD8lo populations for e non-responder FCGS-affected cat at day 0; f responder FCGS-affected cat at day 0; and g responder FCGS-affected cat at 6-month follow-up after ASC treatment. CD8lo percentages of CD8+ cells based on flow cytometry gates shown in e–f for all cats in the study. Non-responder cats had a significantly higher percentage of CD8lo cells before ASC treatment (Mann-Whitney test; p = 0.02)